# Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

> **NCT04874129** · PHASE1 · UNKNOWN · sponsor: **Yooyoung Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** YYC506-T and YYC506-A (phase 1)
- **DRUG:** YYC506 (phase 1)
- **DRUG:** YYC506-T and YYC506-A (phase 2)
- **DRUG:** YYC506 (phase 2)

## Key facts

- **NCT ID:** NCT04874129
- **Lead sponsor:** Yooyoung Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-07
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04874129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04874129, "Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04874129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*